Clinical trial
Safety, Immunogenicity, and Batch Consistency of a Single Dose of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Chinese Healthy Adults Aged 18 Years and Above: a Randomized, Double-blind, Parallel-controlled Clinical Trial
NCT05313646 is registered in ClinicalTrials.gov with Jiangsu Province Centers for Disease Control and Prevention as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Safety, Immunogenicity, and Batch Consistency of a Single Dose of a Recombinant Adenovirus Type-5-vectored COVID-19 Vaccine in Chinese Healthy Adults Aged 18 Years and Above: a Randomized, Double-blind, Parallel-controlled Clinical Trial
- Lead sponsor
- Jiangsu Province Centers for Disease Control and Prevention
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 8, 2021
- Completion date
- September 8, 2021
- Enrollment
- 1,050 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.